Galapagos Crecimiento futuro

Future controles de criterios 0/6

Se prevé que los beneficios de Galapagos disminuyan en un 30.2% al año, mientras que se espera que sus ingresos anuales crezcan en un 3.4% al año. Se prevé que el BPA disminuya en un 36.8% por año. Se espera que la rentabilidad financiera sea de -3.3% en 3 años.

Información clave

-48.1%

Tasa de crecimiento de los beneficios

-47.9%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	24.4%
Tasa de crecimiento de los ingresos	2.1%
Rentabilidad financiera futura	-9.6%
Cobertura de analistas	Good
Última actualización	07 May 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Previsiones de crecimiento de beneficios e ingresos

OTCPK:GLPG.F - Estimaciones futuras de los analistas y datos financieros pasados (EUR Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	286	-99	-679	-416	8
12/31/2025	297	-71	-496	-360	11
12/31/2024	319	-7	-303	-361	11
3/31/2024	244	31	-455	-434	N/A
12/31/2023	240	-4	-425	-406	N/A
9/30/2023	544	-153	-538	-519	N/A
6/30/2023	560	-157	-545	-517	N/A
3/31/2023	548	-181	-565	-533	N/A
12/31/2022	241	-71	-537	-501	N/A
9/30/2022	577	6	-536	-484	N/A
6/30/2022	505	-81	-560	-504	N/A
3/31/2022	507	-126	-503	-445	N/A
12/31/2021	234	-121	-562	-504	N/A
9/30/2021	474	-201	-459	-377	N/A
6/30/2021	537	-219	-507	-421	N/A
3/31/2021	488	-272	-567	-480	N/A
12/31/2020	478	-311	-519	-427	N/A
9/30/2020	455	-368	-579	-510	N/A
6/30/2020	972	75	3,079	3,141	N/A
3/31/2020	948	145	3,156	3,211	N/A
12/31/2019	835	149	3,163	3,209	N/A
9/30/2019	865	280	3,250	3,281	N/A
6/30/2019	324	-66	-211	-193	N/A
3/31/2019	314	-41	-190	-174	N/A
12/31/2018	318	-29	-156	-142	N/A
9/30/2018	255	-74	-166	-156	N/A
6/30/2018	185	-126	-196	-187	N/A
3/31/2018	161	-139	-172	-164	N/A
12/31/2017	156	-116	N/A	-147	N/A
9/30/2017	193	-40	N/A	-51	N/A
6/30/2017	176	-27	N/A	-42	N/A
3/31/2017	177	4	N/A	-35	N/A
12/31/2016	152	54	N/A	239	N/A
9/30/2016	78	-49	N/A	180	N/A
6/30/2016	72	-52	N/A	178	N/A
3/31/2016	55	-68	N/A	170	N/A
12/31/2015	61	-118	N/A	-115	N/A
9/30/2015	75	-72	N/A	-108	N/A
6/30/2015	82	-57	N/A	-96	N/A
3/31/2015	88	-44	N/A	-87	N/A
12/31/2014	90	-37	N/A	-76	N/A
9/30/2014	86	-32	N/A	-53	N/A
6/30/2014	92	-25	N/A	-32	N/A
3/31/2014	94	-21	N/A	-15	N/A
12/31/2013	97	-17	N/A	2	N/A
9/30/2013	55	-10	N/A	-15	N/A
6/30/2013	77	-2	N/A	-33	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que los beneficios de GLPG.F disminuyan en los próximos 3 años (-53.6% al año).

Beneficios vs. Mercado: Se prevé que los beneficios de GLPG.F disminuyan en los próximos 3 años (-53.6% al año).

Beneficios de alto crecimiento: Se prevé que los beneficios de GLPG.F disminuyan en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (3.4% al año) de GLPG.F crezcan más despacio que el mercado de US (7.9% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 3.4% al año) de GLPG.F crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: GLPG.F se prevé que no sea rentable en 3 años.

Galapagos Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Galapagos NV Revises Sales Guidance for the Full Year 2023

Galapagos NV Revises Revenue Guidance of Jyseleca for the Full Year 2022

Recent updates

Galapagos NV Announces Board Changes

Galapagos NV to Present New Preliminary Translational Data at EBMT-EHA Annual Meeting 2024

Alfasigma S.p.A. completed the acquisition of Filgotinib business from Galapagos NV (ENXTAM:GLPG).

Michele Manto to Join Alfasigma and Resigns from His Position as Chief Commercial Officer and Executive Committee Member At Galapagos

Galapagos Announces Start of PAPILIO-1 Phase 1/2 Multiple Myeloma Study of Point-Of-Care Manufactured BCMA CAR-T Candidate, GLPG5301

Galapagos Presents New Encouraging Clinical Data from the Ongoing Phase 1/2 CD19 CAR-T Studies with GLPG5201 and GLPG5101

Galapagos NV to Report First Half, 2024 Results on Aug 01, 2024

Galapagos NV Announces Board Changes

Galapagos NV to Report Q4, 2023 Results on Mar 28, 2024

Galapagos NV Announces Start of Phase 2 Study with Selective Tyk2 Inhibitor, GLPG3667, in Patients with Active Systemic Lupus Erythematosus

Galapagos NV Revises Sales Guidance for the Full Year 2023

Galapagos Appoints Thad Huston as Chief Financial Officer, Effective from July 1, 2023

Galapagos NV Announces Director Changes

Galapagos to Showcase CAR-T Point-Of-Care Manufacturing and Initial Phase 1/2 CLL Data with CD19 CAR-T Candidate, GLPG5201, at the EHA 2023 Congress

Galapagos NV Announces Topline Results from Phase 3 DIVERSITY Trial of Filgotinib in Crohn’s Disease

Galapagos NV Announces Changes in the Executive Committee Effective 1 January 2023

Galapagos and CellPoint Presented Encouraging Initial Data AtASH 2022 for GLPG5101, a CD19 CAR-T Candidate Manufactured At Point-Of-Care

Galapagos Announces CHMP Adoption of PRAC’s Recommendation for Jyseleca® Following Extensive Safety Review of all JAK Inhibitors

Galapagos NV to present encouraging initial data from FILOSOPHY real-world arthritis study at ACR Convergence 2022

Galapagos NV to Report Fiscal Year 2022 Final Results on Mar 23, 2023

Galapagos NV to Report Q1, 2023 Results on May 04, 2023

Galapagos Receives Positive CHMP Opinion for Jyseleca® European Label Update Based on Testicular Function Safety Data from MANTA/RAy Studies

Galapagos NV announced that it has received €3.07625 million in funding

Galapagos NV Revises Revenue Guidance of Jyseleca for the Full Year 2022

Galapagos NV (ENXTAM:GLPG) entered into a definitive agreement to acquire Abound Bio, Inc. for $14 million.

Galapagos NV announced that it expects to receive €1.459507 million in funding

Galapagos NV to Report Q3, 2022 Results on Nov 03, 2022

Galapagos NV Announces Executive Appointments

Galapagos NV Announces Approval of Additional Indication Based on Phase 2B/3 SELECTION Study in Patients with Moderate-To-Severe Ulcerative Colitis

Galapagos Provides Further Insights into the Treatment of Ulcerative Colitis At the European Crohn’s and Colitis Organization Annual Congress

Galapagos NV Announces Authorization of Medicines and Healthcare Products Regulatory Agency for Jyseleca (Filgotinib), as New Treatment for Ulcerative Colitis in Great Britain

Galapagos Nv Completes Patient Recruitment for Mangrove Phase 2 Trial with GLPG2737 in Polycystic Kidney Disease

Galapagos Announces Positive CHMP Opinion for Jyseleca® (Filgotinib) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis

Galapagos NV Demonstrates Early Clinical Activity with SIK2/3 Inhibition in Inflammation

Galapagos NV Announces That Primary and Secondary Endpoint Results from the Phase 3 SELECTIONinduction

Galapagos NV to Present Data on Rheumatoid Arthritis At the Upcoming European League Against Rheumatism (EULAR) Congress

Galapagos Announces First Patient Enrolled in FILOSOPHY Study to Advance Understanding of Jyseleca (Filgotinib) Effectiveness and Safety in A Real-World Setting

Galapagos Reports Primary Endpoint for the Ongoing Filgotinib MANTA and MANTA-RAy Safety Studies

Galapagos NV to Report Fiscal Year 2020 Final Results on Mar 25, 2021

Galapagos and Gilead discontinue ISABELA Phase 3 trials in IPF

Galapagos NV to Report Fiscal Year 2021 Results on Feb 24, 2022

NICE Recommends Galapagos Jyseleca (Filgotinib) on NHS in Decision for Rheumatoid Arthritis

Selvita S.A. (WSE:SLV) completed the acquisition of Fidelta D.O.O. from Galapagos NV (ENXTAM:GLPG).

Gilead Sciences, Inc. and Galapagos NV Announce New Commercialization and Development Agreement for Jyseleca® (Filgotinib)

Galapagos NV Reports Positive Topline Results with GLPG1205 in IPF Patients in PINTA Proof-of-Concept Trial

Galapagos NV Announces First Dosing in MANGROVE Phase 2 Trial with GLPG2737 in Polycystic Kidney Disease

Selvita S.A. (WSE:SLV) signed an agreement to acquire 100% stake in Fidelta D.O.O. from Galapagos NV (ENXTAM:GLPG) for an enterprise value of €31.2 million.

Galapagos NV Announces Dosing of the First Psoriasis Patient in the Phase 1B Trial with GLPG3667

Gilead Sciences, Inc. and Galapagos NV Announce the Application for A New Indication to the Approved License

Galapagos NV Unveils the Toledo Target Family as a Series of Salt-Inducible Kinase Inhibitors

Galapagos and Servier Report Topline Results for Roccella Phase 2 Clinical Trial with Glpg1972/S201086 in Knee Osteoarthritis Patients

Phase 2B/3 Trial Shows Efficacy of Filgotinib for the Induction and Maintenance of Remission in Moderately and Severely Active Ulcerative Colitis

Galapagos Announces First Dosing with Toledo compound GLPG3970 in psoriasis trial

Galapagos NV announces European Commission Grants Marketing Authorization for Jyseleca (Filgotinib) for the Treatment of Adults with Moderate to Severe Active Rheumathoid Arthritis

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento